Roche Keeps Shopping: Mirus Acquisition Bolsters RNAi Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will pay $125 million for access to Wisconsin-based Mirus’ Dynamic PolyConjugates technology.
You may also be interested in...
Roche's Transfer Of Assets To Arrowhead May Create Most-Comprehensive RNAi Firm
After an expensive foray into RNAi, Roche is handing off its substantial portfolio to Arrowhead, in exchange for a 10% stake in the company and right-of-first-negotiation to programs and earn-out potential.
Roche's Transfer Of Assets To Arrowhead May Create Most-Comprehensive RNAi Firm
After an expensive foray into RNAi, Roche is handing off its substantial portfolio to Arrowhead, in exchange for a 10% stake in the company and right-of-first-negotiation to programs and earn-out potential.
Roche Assures Investors: “Right Moment Is Now” To Acquire Genentech
Roche would consider another Genentech-like deal, but the biotech itself has grown too large and the time is right to bring it in-house, Humer says.